尤瑞克林治疗分水岭脑梗死效果及其对血清S-100B蛋白及神经元特异性烯醇化酶的影响  

Effect of human urinary kallidinogenase injection on cerebral watershed infarction and its influence on neuron specific enolase and S100B

作　　者：白伟利[1] 侯瑞生 秦伟伟[1] 谢卫征[1] 张树青[1] 马大伟[1] 

机构地区：[1]安阳市第六人民医院神经内科,安阳455000 [2]河南国际旅行卫生保健中心,郑州450003

出　　处：《中华实用诊断与治疗杂志》2016年第6期617-619,共3页Journal of Chinese Practical Diagnosis and Therapy

基　　金：安阳市科技发展计划基金项目(150153)

摘　　要：目的探讨尤瑞克林治疗急性分水岭脑梗死(cerebral watershed infarction,CWI)的效果及其对患者血清S-100B蛋白、神经元特异性烯醇化酶(neuron specific enolase,NSE)水平的影响。方法 120例急性CWI患者随机分为观察组和对照组各60例,对照组给予抗血小板等常规治疗,观察组在对照组治疗基础上给予尤瑞克林0.15PNAU+生理盐水100mL,静脉滴注,1次/d,连续应用14d。分别于治疗前及治疗7、14d后检测2组血清S-100B蛋白、NSE水平,应用美国国立卫生研究院卒中量表(National Institute of Health Stroke Scale,NIHSS)评分评估2组神经功能缺损情况,治疗后14d评定临床疗效,治疗后30、90d行Barthel指数评分评定患者日常生活活动能力,并进行比较。结果观察组治疗7、14d后S-100B蛋白[(2.6±1.3)、(2.3±1.2)μg/L]、NSE[(5.6±3.1)、(4.8±2.3)μg/L]均低于治疗前[(6.3±2.6)、(16.9±6.5)μg/L](P<0.05);对照组治疗14d后S-100B蛋白[(3.0±1.6)μg/L]、NSE[(6.3±2.9)μg/L]低于治疗前[(7.0±3.0)、(17.6±6.8)μg/L](P<0.05);2组治疗14d后S-100B蛋白、NSE水平比较差异无统计学意义(P>0.05);观察组、对照组治疗14d后NIHSS评分[(3.6±1.7)、(6.6±2.5)分]均较治疗前[(11.9±4.0)、(10.3±4.8)分]降低(P<0.05),且观察组低于对照组(P<0.05);治疗14d后观察组有效率(91.7%)高于对照组(66.7%)(P<0.05);观察组治疗30、90d后Barthel指数评分[(79.2±11.2)、(89.4±12.9)分]高于治疗前[(53.2±10.6)分](P<0.05);对照组治疗90d后Barthel指数评分[(78.0±12.2)分]高于治疗前[(54.6±12.2)分](P<0.05);观察组治疗30、90d后Barthel指数评分高于对照组(P<0.05)。结论急性CWI患者在常规治疗基础上应用尤瑞克林治疗可降低血清S-100B蛋白、NSE水平,改善患者神经功能缺损,提高疗效。Objective To explore the therapeutic effect of human urinary kallidinogenase injection on cerebral watershed infarction（CWI）,and its influence on the levels of S-100 Band neuron specific enolase（NSE）.Methods A total of 120 patients with acute CWI were randomly divided into observation group and control group,with 60 patients in each group.Control group was given conventional treatment as anti-platelet aggregation.Observation group was given intravenously injection of 0.15 PNAU of urinary kallidinogenase in 100 mL normal saline once a day totally for 14 days,based on the treatment in control group.The serum levels of NSE and S-100 Bprotein were detected before and after 7-and 14-day treatment,the neurological function deficiency was evaluated by National Institute of Health Stroke Scale（NIHSS）,and the clinical effect was assessed after 14-day treatment.The activity of daily life（ADL）and Barthel index were calculated after 30-and 90-day treatment and compared between two groups.Results After 7-and 14-day treatment,the levels of S-100B（（2.6±1.3）,（2.3±1.2）μg/L）and NSE（（5.6±3.1）,（4.8±2.3）μg/L）were significantly lower than those before treatment（（6.3±2.6）,（16.9±6.5）μg/L）in observation group（P〈0.05）.The levels of S-100 Band NSE were significantly lower after 14-day treatment（（3.0±1.6）,（6.3±2.9）μg/L）than those before treatment（（7.0±3.0）,（17.6±6.8）μg/L）in control group（P〈0.05）.There were no significant difference in S-100 Band NSE levels after14-day treatment between two groups（P〈0.05）.The NIHSS scores after 14-day treatment（3.6±1.7,6.6±2.5）were significantly higher than those before treatment（11.9±4.0,10.3±4.8）in observation group and control group（P〈0.05）,and were significantly lower in observation group than those in control group（P〈0.05）.The effective rate was significantly higher in observation group（91.7%）than that in control group（66.7%）（P〈0.05）.The Barthel index was sig

关 键 词：分水岭脑梗死 尤瑞克林 S-100B蛋白 神经元特异性烯醇化酶 卒中量表评分 Barthel指数评分 

分 类 号：R743.3[医药卫生—神经病学与精神病学]